First Patient Dosed in TeLuRide-008 Ph 2/3 Trial of EIK1001 in NSCLC
“Treating the first patient in TeLuRide-008 is a significant milestone for Eikon as we continue to advance EIK1001 in multiple indications, with the ultimate goal of delivering improved outcomes to patients with significant unmet need,” said Roy Baynes, M.D., Ph.D. Chief Medical Officer of Eikon. “Despite advancements in NSCLC, the current standard of care was established over a decade ago and does not deliver durable benefit for many patients. EIK1001 is designed to drive an enhanced immune response by stimulating both innate and adaptive immunity, improving antigen presentation in secondary lymphoid tissues and recruiting a broader répertoire of T-cells. We are grateful to the patients and investigators participating in this study who are vital partners as we work to develop therapies that may deliver more meaningful and sustained responses for people living with cancer.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the